ESTRO Multidisciplinary Management of Breast Cancer 2017

Observed absolute breast cancer mortality benefit in pN0 women by size of absolute recurrence benefit

Predicted absolute benefit: Large (20+ %)

Predicted absolute benefit: Intermediate (10-19%) Large Intermediate Lower

Predicted absolute benefit: Lower (<10%)

1924 pN0 women

3763 pN0 women

1600 pN0 women

22

Lancet, 2011